Hansa Biopharma has reported positive Phase III trial results for imlifidase, an enzyme that rapidly removes anti-HLA antibodies, enabling highly sensitized kidney transplant patients to receive organs more effectively. The trial involving 64 advanced kidney disease patients showed significantly improved mean estimated glomerular filtration rate at 12 months (51.5 mL/min) compared to controls (19.3 mL/min). The therapy accelerated access to transplants and improved kidney function, positioning Hansa for a Biologics License Application submission by year-end. This approach addresses a critical unmet need in transplant immunology for antibody desensitization.